Cadrenal Therapeutics, Inc. Common StockCVKDNASDAQ
Loading
SG&A Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+61.4%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
+61.4%/yr
Annual compound
Percentile
P100
Near historical high
vs 3Y Ago
4.2x
Strong expansion
Streak
3 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$9.70M+43.6%
2024$6.75M+90.3%
2023$3.55M+53.8%
2022$2.31M-